All compounds
GLP-1 and metabolicClinical-stage compound

Cagrilintide

A long-acting amylin analogue being studied for weight management, including in combination with semaglutide.

Reference reviewed 5 September 2026 · No dosing or protocol information
01

What the name refers to

A long-acting amylin analogue being studied for weight management, including in combination with semaglutide.

02

Evidence and regulatory context

Human clinical research exists, but this entry is not a broadly authorised consumer medicine. Trial results apply to the studied formulation, population and endpoints—not automatically to products sold online.

03

Reading product records

Keep evidence from an authorised or trial formulation separate from an online vial carrying the same name. Product records should identify the exact active ingredient and form, measured peptide amount, batch, storage history and whether the document covers identity, quantity or both.

04

Primary research links

Use current regulator and study records rather than treating a catalogue description as medical evidence.